1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. The GRASP program supports data-science research in Africa to stimulate progress. While the provided information is an award notice, it indicates an active program with a performance end date in July 2026, suggesting ongoing or upcoming related opportunities.
The NIH supports a diverse mix of research projects in Sub-Saharan Africa.
Get alerted about grants like this
Save a search for “National Heart, Lung, and Blood Institute (NHLBI) / NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Further details on specific eligibility for new applications would need to be confirmed on the official NIH or Grants.gov website, but generally NIH funds research from U.S. universities collaborating internationally. Confirm the full requirements in the official notice before applying.
Applications for Growing Data-science Research in Africa to Stimulate Progress (GRASP) are due July 31, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is funded by National Heart, Lung, and Blood Institute (NHLBI) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This program supports small businesses in accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders. It is a Phase IIB Bridge Award, indicating it targets projects that have already demonstrated success in earlier SBIR/STTR phases.
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This Notice of Funding Opportunity invites small businesses to submit SBIR grant applications to support later stage research and development (Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and address rare diseases or young pediatr…
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This NOFO invites eligible United States small business concerns (SBCs) to submit STTR Phase I and Fast-Track grant applications. The NHLBI will support Phase I and Fast-Track applications from early-career scientists and investigators with data science, artificial intelligence/machine learning, engineering, clinical care and other biomedical backgrounds who are new to the NIH SBIR/STTR programs. Applications submitted to this NOFO are not allowed to propose clinical trial(s).
NIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read articlePAR-26-042 funds NLM-priority clinical informatics R01 grants up to $250,000 in direct costs per year through March 6, 2029, with standard NIH cycles on October 5, February 5, and June 5. The notice explicitly defines non-responsive applications: incremental tool improvements, projects primarily focused on social determinants of health, and projects primarily focused on ethical/legal/social issues. With NIH SBIR/STTR just reopened and the OMB Uniform Grants Regulation rewrite reshaping discretionary awards, the NLM clinical informatics line is one of the few stable, well-defined biomedical funding streams left at the agency. Here is how to read it.
Read article